Document Detail


Tolvaptan.
MedLine Citation:
PMID:  20205486     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tolvaptan is an orally administered, nonpeptide, selective arginine vasopressin V(2) receptor antagonist that increases free water clearance, thereby correcting low serum sodium levels. SALT-1 and -2, two identical, randomized, double-blind, placebo-controlled, multicentre trials, included patients with hypervolaemic or euvolaemic hyponatraemia (serum sodium <135 mmol/L) associated with heart failure, cirrhosis or the syndrome of inappropriate antidiuretic hormone secretion. In both trials, patients receiving (in addition to standard medical treatment) tolvaptan 15-60 mg once daily (titrated according to response) for up to 30 days (n = 95 and 118) experienced significantly greater improvements than those receiving placebo (n = 89 and 114) for the co-primary endpoints of the change in average daily area under the curve for the serum sodium level from baseline to day 4 and from baseline to day 30. This beneficial effect of tolvaptan on serum sodium levels in SALT-1 and -2 was observed in patients with mild (serum sodium <135 mmol/L) and in those with marked (serum sodium <130 mmol/L) hyponatraemia at baseline. Tolvaptan was also superior to placebo in increasing serum sodium levels from baseline to day 7 in a subgroup of 323 patients with hyponatraemia (serum sodium <134 mmol/L) in the randomized, double-blind, multicentre EVEREST trials, which included patients who were hospitalized for worsening heart failure. Tolvaptan was generally well tolerated in clinical trials. The most frequently reported adverse events were thirst and dry mouth, which result from the pharmacodynamic effects of the drug.
Authors:
Greg L Plosker
Related Documents :
6351206 - Influence of prostaglandin a1 on renal filtration, hemodynamics and excretion. investig...
2824366 - Ouabainlike na+,k+-atpase inhibitor in the plasma of normotensive and hypertensive huma...
235746 - Diuretics, urate excretion and sodium reabsorption: effect of acetazolamide and urinary...
2145876 - The atrial natriuretic factor hormonal system in the regulation of sodium excretion in ...
19106286 - The prevalence of low triiodothyronine according to the stage of chronic kidney disease...
12019616 - Melengestrol acetate blocks the preovulatory surge of luteinizing hormone, the expressi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  70     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-08     Completed Date:  2010-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  443-54     Citation Subset:  IM    
Affiliation:
Adis, Auckland, New Zealand. demail@adis.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzazepines / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Humans
Hyponatremia / drug therapy*,  etiology
Receptors, Vasopressin / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Receptors, Vasopressin; 150683-30-0/tolvaptan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar ...
Next Document:  Pilsicainide.